Esophageal Cancer Market Analysis

Global Esophageal Cancer Market Overview

Esophageal Cancer Market Size was valued at USD 13.09 Billion in 2023. The Esophageal Cancer market industry is projected to grow from USD 14.2 Billion in 2024 to USD 24.64 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.23% during the forecast period (2024- 2032). An increase in the use of oral drugs and better healthcare system infrastructure are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Esophageal Cancer Market Trends

• Growing research efforts are driving the market growth

Market CAGR for esophageal cancer is driven by the rising spending on identifying novel drugs to treat the disease. The esophageal cancer market is anticipated to expand in the coming years due to increasing expenditure on research and development and industry leaders' introduction of new products. Governments and non-profit organizations are trying to raise public awareness of esophageal cancer in some countries. Oncologists and other cancer specialists have recently been interested in esophageal cancer research. The medical community's renewed focus on esophageal cancer is mainly on the fact that there are countless diseases to which it can lead. In addition, oncologists are concerned about the rising prevalence of cancer due to exposure to carcinogens found in certain diets. Thus, the expansion of the worldwide esophageal cancer market is mostly dependent on the medical industry's initiatives to reduce the prevalence of the disease.

Additionally, age, gender, tobacco use, alcohol consumption, Barrett's esophagus, obesity, and achalasia are all major contributors to esophageal cancer. Demand for treatments for esophageal cancer is expected to rise for these causes. Esophageal cancer medicine demand will increase as more patients choose combined therapy methods. Combination chemotherapy is the most effective treatment for esophageal cancer. This strategy aims to provide the most effective treatment possible for esophageal cancer by combining the benefits of other treatments, such as chemotherapy and targeted therapy. It also incorporates techniques like chemotherapy, irradiation, and surgery to improve patient outcomes and survival rates, such as perioperative chemotherapy or final chemoradiation.

For instance, Roche has announced the establishment of the Institute of Human Biology (IHB), which will foster progress in studying human organs and other human model systems. By advancing knowledge of organ function and disease progression through human model systems, the center hopes to hasten drug discovery and development. As a result, the demand for esophageal cancer is anticipated to increase throughout the projection period due to rising awareness. Thus, the driving factor is esophageal cancer market revenue.

Esophageal Cancer Market Segment Insights

Esophageal Cancer Type Insights

The esophageal cancer market segmentation, based on type, includes esophageal squamous-cell carcinoma and esophageal adenocarcinoma. In 2022, the esophageal squamous-cell carcinoma segment led the esophageal cancer market in revenue because about 90% of the 456,000 new cases of esophageal cancer each year are caused by esophageal squamous cell carcinoma (ESCC), according to the national institute of health. Eastern and central Asia, the Rift Valley in eastern Africa, and southern Africa are hotspots for the disease. Different factors contribute to ESCC in different areas. Although early research linked cigarette smoking and strong alcohol consumption to high ESCC rates in France, these characteristics cannot account for the high frequency in other countries.

Figure 1 Esophageal Cancer Market by Type, 2023 & 2032 (USD Billion)                                  

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Esophageal Cancer Phases Insights

The esophageal cancer market segmentation, based on phases, includes Phase I, Phase II, and Phase III. The phase II segment is expected to develop at a CAGR of 8.22% over the projected period, making up the largest market share due to patients with stage 2 esophageal cancer who refuse surgery and may be provided chemotherapy as the primary therapeutic option. Stage 2 esophageal cancer is typically treated with chemotherapy medications, including capecitabine (Xeloda), cisplatin, and capecitabine.

Esophageal Cancer Treatment Insights

The esophageal cancer market segmentation, based on treatment, includes surgery, chemotherapy, and radiotherapy. The chemotherapy segment with the largest market share in expected to grow fastest at a CAGR of 8.22% over the next several years. Because to put it simply, chemotherapy is the employment of drugs to eradicate cancer cells. Chemotherapy drugs come in many forms but accomplish the same goals. They inhibit cancer cells from dividing, which stops the disease from spreading.

Esophageal Cancer Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Esophageal Cancer market will dominate because of rising esophageal cancer rates, the world's top researchers and developers, and a well-established approval process framework. In addition, with an increased number of physicians, improvements in treatment effectiveness, and the rise of sedentary lifestyles because of these factors, the esophageal cancer market is expected to expand in the coming years.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 ESOPHAGEAL CANCER MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe’s esophageal cancer market accounts for the second-largest market share because of improvements in medical infrastructure, an increase in generic-drug producers, new government programs, and the growth of niche-focused online communities. Further, the German esophageal cancer market held the largest market share, and the UK esophageal cancer market was the fastest-growing market in the European region.

The Asia-Pacific esophageal cancer market is expected to grow at the fastest CAGR from 2023 to 2032 because of increased esophageal cancer medication clinical trials in Asia—the rising prevalence of esophageal cancer and the accessibility of attractive reimbursement systems. Moreover, China’s esophageal cancer market held the largest market share, and the Indian esophageal cancer market was the fastest-growing market in the Asia-Pacific region.

Esophageal Cancer Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the esophageal cancer market grow even more. There are some strategies for action that market participants are implementing to increase their presence around the world's  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the esophageal cancer industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturer use in the esophageal cancer industry to benefit clients and increase the market sector. In recent years, the esophageal cancer industry has offered some of the most significant technological advancements. Major players in the esophageal cancer market, including Amgen, Eli Lilly, and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Merck & Co., and others are attempting to increase market demand by investing in research and development operations.

Amgen's mission is to find, create, manufacture, and distribute novel human medicines to benefit patients with life-threatening illnesses. A fundamental goal of this method is to answer fundamental issues about human biology by employing state-of-the-art human genetics and other methods. Amgen employs its expertise to target areas with significant medical needs, intending to develop treatments that drastically enhance patients' quality of life. Amgen has been a leader in the biotechnology industry since its founding in 1980. The company has treated millions of patients worldwide and is now working on innovative medications that could revolutionize the industry. Amgen is included in the Dow Jones Industrial Average and the Nasdaq-100 indices. Amgen was designated one of Forbes' "World's Best Employers" and one of Barron's "America's 100 Most Sustainable Companies" in 2022. In May 2023, Amgen and TScan Therapeutics, Inc. established a multi-year agreement to identify the antigens identified by T cells in Crohn's disease patients using TScan's unique target identification technology, TargetScan.

Merck, or MSD outside of North America, has one common goal to save and improve people's lives worldwide by applying cutting-edge research. We have given people a reason to believe in the future for more than 130 years, thanks to the creation of life-saving medicines and vaccinations. Today, we are at the vanguard of research to bring you better health solutions that improve illness avoidance and treatment in human and animal populations. Tomorrow, we hope to be the world's preeminent research-intensive biopharmaceutical firm. Every day, we fight to create a secure, all people and communities that may have a bright, healthy, and sustainable future worldwide by cultivating a diverse and inclusive workforce and acting ethically. In April 2023, Moderna, Inc., the world's leading developer of messenger RNA (mRNA) therapeutics and vaccines, in addition to Merck (MSD outside of North America), presented the first detailed results from their Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti- I. 

Key Companies in the Esophageal Cancer market include

• Amgen


• Eli Lilly and Company


• Hoffmann-La Roche


• Bristol-Myers Squibb Company


• Boehringer Ingelheim GmbH


• Bristol-Myers Squibb


• GlaxoSmithKline Plc.


• Novartis AG


• Johnson & Johnson


• Gilead Sciences


• Merck & Co.

Esophageal Cancer Industry Developments

May 2023 Amgen collaborators at the Association of Black Cardiologists (ABC) and Morehouse School of Medicine (MSM) have started the African American Heart Study to check out the association between Lp (a) and atherosclerotic cardiovascular disease (ASCVD). Five thousand African Americans from the United States will participate in the study. Atherosclerotic cardiovascular disease (ASCVD) involves cardiac arrest and cerebrovascular accident, both caused by cholesterol plaque in the arteries.

March 2023 GSK plc and SCYNEXIS, Inc. have purchased the rights to commercialize Brexafemme worldwide. The FDA has approved Brexafemme (ibrexafungerp tablets) to treat and prevent vulvovaginal candidiasis (VVC) in the United States. 

Esophageal Cancer Market Segmentation

Esophageal Cancer Type Outlook

• Esophageal Squamous-Cell Carcinoma


• Esophageal Adenocarcinoma

Esophageal Cancer Phase Outlook

• Phase I


• Phases II


• Phases III

Esophageal Cancer Treatment Outlook

• Surgery


• Chemotherapy


• Radiotherapy

Esophageal Cancer Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America